Final-Program-ATS-2023-AP.vp

SUNDAY • MAY 21

61

P1095 Feasibility and Acceptability of Goals of Care Elicitation in an Emergency Department Setting/ S.R. Yapalater, Philadelphia, PA P1096 Listen Don’t Reload: Discussing Racism and Healthcare With Racially Marginalized Patients With Serious Illness/ C.E. Brown, Seattle, WA P1097 Palliative Care Ad-hoc and Largely Unknown in Rural Chronic Disease - a Cross Sectional Service-Level Survey/ R. Disler, Melbourne, Australia P1098 Palliative Approach Remains Lacking in Terminal Admissions for Chronic Disease: A Five Site Retrospective Medical Record Audit/ R. Disler, Melbourne, Australia P1099 The “Heart” of CHART: A Qualitative Analysis of an Informed Assent Approach to Discussing CPR With Inpatients With Advanced Medical Comorbidities/ S. Sexauer, Charleston, SC P1100 How Much Do Patient Preferences Really Matter When Predicting Their Risk for Invasive Mechanical Ventilation in the ICU?/ G.E. Weissman, Philadelphia, PA P1101 The Utility of Triggers to Prompt Specialty Palliative Care Consultation in the Intensive Care Unit/ J. Treadway Nomitch, Seattle, WA P1102 Using Human-Centered Design to Refine and Target an ICU Communication Intervention/ M. Modes, Los Angeles, CA P1103 Stakeholder Perspectives on Family Caregiving After Critical Illness: A Qualitative Content Analysis/ A.C. Moale, Pittsburgh, PA P1104 Evaluation of Morphine and Oxygen Use in Terminally Ill Adult Patients With Dyspnea in Two Public Hospitals in Brazil: A Cross-sectional Study/ L. Stanzani, Brasilia, Brazil P1105 Surrogate Trust in the Intensive Care Unit: An Evaluation of Trust Levels in Physicians and the Healthcare System/ A. Kazi, Philadelphia, PA

P104 Neonatal Alveolar Macrophages Undergo Metosis in an Inflammatory Model of Lung Injury/ R. Higazy, Toronto, Canada P105 Sepsis-Induced Immune Paralysis: Of Monocytes and Metabolites/ L.K. Torres, New York, NY P106 Harnessing the Immune System for Treatment of Idiopathic Pulmonary Fibrosis/ A. Bhattacharyya, San Francisco, CA P107 Pharmacological Activation of Cannabinoid-2 Receptor Reduces SARS-CoV-2-Spike Protein-Induced Acute Lung Injury and Inflammation/ J. Lockett, Norfolk, VA P108 Murine Hepatitis Virus-1 ß2-Coronavirus Pulmonary Infection and Subsequent Exposure to Fio2=0.60 but Not 0.30 Synergistically Worsen Survival and Lung Injury in a Mouse Model/ X. Cui, Bethesda, MD P109 Assessing the Clinico-Immunological Profile of Patients With Obesity and Chronic Rhinosinusitis/ M. Chaaban, Cleveland, OH P110 HAQ and AQ STING/MPYS Are Resistant to STING-Mediated T Cell Death/ L. Jin, Gainesville, FL P111 Insights on Interferon-Independent Induction of Interferon-Stimulated Genes in the Airway at Early Stage of SARS-CoV-2 Infection: Human and In Vivo/ H.J. Kim, Seoul, Korea, Republic of P112 The Role of sNASP-TRAF6 Axis in Diesel Exhaust Particles-Exacerbated Allergic Inflammation/ F.-M. Yang, Taipei, Taiwan P113 Identification and Verification of an Allergen-Induced Cell Surface Signature in Dendritic Cells/ M. Sia, Orlando, FL

BEHAVIORAL • CLINICAL THEMATIC POSTER SESSION

A34

IDENTIFYING AND IMPROVING PALLIATIVE CARE NEEDS ACROSS THE CARE CONTINUUM

BEHAVIORAL • CLINICAL THEMATIC POSTER SESSION

9:00 a.m. - 4:15 p.m.

Walter E. Washington Convention Center Area K, Hall C (Lower Level)

A35

LEVERAGING USE OF INFORMATICS AND TECHNOLOGY

Viewing: Posters will be on display for entire session

11:30-1:15

Discussion: 11:30-12:15 authors will be present for individual discussion 12:15-1:15 authors will be present for discussionwith assigned facilitators. P1093 Trends in Utilization of ICU for Older Adults With Cancer at the End-of-Life/ S. Jain, New Haven, CT P1094 How Important Is Spirometry for Identifying Patients With Chronic Obstructive Pulmonary Disease Who Are Appropriate for Palliative Care?/ A.V. Lange, Aurora, CO

9:00 a.m. - 4:15 p.m.

Walter E. Washington Convention Center Area E, Hall C (Lower Level)

Viewing: Posters will be on display for entire session

11:30-1:15

Discussion: 11:30-12:15 authors will be present for individual discussion

12:15-1:15 authors will be present for discussionwith assigned facilitators.

ATS 2023 • Washington, DC